News

The drug industry is not happy about a new plan from the Trump administration that would allow cheaper drugs to be imported from Canada. The initiative, called the Safe Importation Action Plan, was announced by HHS July 31.

Average Medicare Part D premiums have dropped for the third year in a row, according to CMS, and they are projected to decline again in 2020. Medicare Part D plans offer prescription drug coverage to Medicare beneficiaries.

The FDA accepted 137 new drug approvals (NDAs) and biologics license applications (BLAs) in 2018, up 11% from 2017 and 36% from 2012 to 2017, according to a new report.

In the second round of presidential debate of Democratic candidates, the hopefuls took on healthcare right away, debating Medicare-for-all proposals and a public option on stage. The arguments over healthcare “set a combative tone” for the rest of the debate.

HHS is launching a new action plan for the safe importation of certain prescription drugs to bring in medications from foreign markets. The Safe Importation Action Plan extends recent initiatives from the Trump administration to make prescription drugs cheaper in the U.S.

Kaiser Permanente, a major health and hospital system based in California, has appointed its first-ever chief digital officer. Prat Vemana will assume the role August 12.

Just a day after announcing three new payment proposals for 2020, CMS introduced a new pilot program for clinicians focusing on data.

Minnesota-based Mayo Clinic is the nation’s best hospital for 2019-2020, according to U.S. News & World Report, which ranked hospitals overall and based on specialties.

CMS unleashed a slew of proposals July 29, including 2020 payment rule proposals and a requirement for hospitals to publish the payer-specific negotiated prices of healthcare services.

Seemingly innocuous web browser extensions are actually a gateway for health and other data to be collected––and even put up for sale, according to Geoffrey Fowler, technology columnist for The Washington Post.

Pfizer, one of the nation’s largest pharmaceutical companies, is merging its off-patent and generic drug business with Mylan, a global generic and specialty pharmaceutical company based in the Netherlands. The spinoff deal is expected to close mid-2020, pending shareholder and regulatory approvals.

President Trump is reportedly working on another executive order targeting rising drug prices, according to Reuters.